Delivering measurable value through clinical expertise, program transparency, and superior service.
Choosing the right workers’ compensation pharmacy benefit manager (PBM) is a critical decision—one that directly impacts injured worker safety, clinical outcomes, and total claim cost. In CompPharma’s 20th Annual Prescription Drug Management in Workers’ Compensation Survey, industry professionals once again ranked MyMatrixx as the #1 PBM, a position we’ve proudly held since 2019.
With an overall score of 4.29 out of 5, MyMatrixx scored 21% higher than the average PBM evaluated in the survey. This recognition reflects more than reputation—it’s based on real‑world experience and reinforces the measurable value MyMatrixx delivers every day to the workers’ compensation community.
Industry Recognition That Matters
CompPharma, an independent consulting and research firm, surveyed 20 workers’ compensation professionals—including decision makers, clinical leaders, and operations staff representing state funds, carriers, self‑insured employers, guarantee funds, and third‑party administrators. Participants evaluated PBMs based on perception, reputation, and firsthand experience, with scores ranging from “1,” meaning “would not work with,” to “5,” meaning “would highly recommend.”
20th Annual CompPharma
survey results
MyMatrixx ranked
#1 PBM by the industry
MyMatrixx claims with
opioid spend dropped
5.9%
MyMatrixx Customer Service ranked #1 scoring 4.8 out of 5
“Being ranked by the industry as the #1 PBM is incredibly meaningful because it’s driven by the voices of our clients and partners,” said Paul King, President of MyMatrixx by Evernorth. “It reinforces our commitment to deliver clinical quality, program transparency, and superior service. This recognition motivates us to keep innovating and delivering meaningful value—ensuring injury‑related medications are safe, effective, accessible, and affordable.”
What the Industry Values—and Why MyMatrixx Leads
The survey highlights several areas where MyMatrixx consistently stands apart:
Best‑in‑Class Customer Service
MyMatrixx earned the highest customer service score, ranking 4.8 out of 5.
“Taking care of our clients is what it’s all about,” King shared. “A big part of this success is our 100% in‑house customer service team.”
Before taking a single call, team members complete extensive, role‑specific training to ensure they are prepared to listen, communicate clearly, and take action in the best interest of both clients and injured workers. Our service model includes 24/7 availability and live chat support, delivering responsive, informed assistance when it matters most.
Deep Clinical Expertise
With over 30 clinicians on staff, MyMatrixx brings the scale and expertise needed to proactively manage medication utilization, control costs, , identify trends and challenges, and improve outcomes. This clinical team—supported by comprehensive claims, pharmacy, and workers’ compensation data—provides informed analysis and targeted recommendations to address today’s most pressing challenges, including:
- Reducing opioid utilization (the survey reports a 5.9% year‑over‑year drop in opioid claims)
- Controlling high‑cost topical medications
- Managing the use of GLP‑1 medications
- Curbing physician dispensing
Industry‑Leading Network Penetration
Network penetration drives cost control, consistency, and clinical integrity across every prescription. MyMatrixx delivers this at scale, achieving a 91.3% network penetration rate through our proprietary national pharmacy network, advanced point‑of‑sale controls, and comprehensive out‑of‑network (OON) strategies.
Our solutions address third‑party bills, mixed bills, physician‑dispensed medications, and Direction of Care scenarios—helping capture, convert, and manage the approximately 30% of prescriptions that process out of network, while driving meaningful cost savings.
Transparency That Informs Better Decisions
“Transparency means understanding,” explained King. At MyMatrixx, transparency goes beyond reporting—it empowers clients with clarity and confidence. We ensure clients understand:
- Their pharmacy program performance, outcomes, and financial guarantees
- What they are paying for—and why
- Medication changes including FDA approvals, recalls, and safety issues
- The impact of regulatory actions at the state level
- Emerging industry trends and challenges
“At MyMatrixx, transparency means we are working with our clients toward the same goals to achieve positive outcomes,” King added.
An Innovative Outlook Focused on the Future
MyMatrixx continues to invest in data, technology, and innovation to help clients make smarter, faster decisions. Our evolving solutions include:
- An enhanced MyPassport® portal, designed for improved usability and access to critical information
- A game‑changing, real-time, prior authorization decision support tool that delivers insight supported by clinical, regulatory, and industry guidelines
- Expanded automation and artificial intelligence (AI) capabilities that create a more personalized, efficient experience—freeing claims professionals to focus on complex, high‑impact cases
Ready for What’s Next
“MyMatrixx clients expect a lot from us—and we like that,” said King. “We rise to the challenge.”
We’re honored by the industry’s continued recognition as the #1 PBM, and we remain focused on what matters most: working alongside our clients to advance the quality, safety, and efficiency of workers’ compensation pharmacy benefits and deliver measurable value for the workers’ compensation community.
About CompPharma
CompPharma, an independent consulting and research firm, works with payers and pharmacy benefit managers (PBMs) to bring transparency into workers’ compensation pharmacy programs. Since 2004, the firm has surveyed workers’ compensation payers on managing the cost of prescription drugs. The goal of the survey is to gain insight into the major cost drivers, management approaches, problems, and trends that decision makers face — and how they are working to control costs and meet clinical goals. Results were gathered by combining their input with analysis of pharmacy data from 2023 and 2024.